Expansion through acquisition US BioTek Laboratories has a track record of expanding its diagnostic testing portfolio through strategic acquisitions, like the recent acquisition of Realtime Laboratories. Leveraging this growth strategy, there are opportunities to target similar companies for potential acquisitions to further enhance the company's offerings.

Innovative testing solutions With the launch of specialty tests like Monkeypox and At-Home COVID-19 tests, US BioTek Laboratories demonstrates a commitment to offering innovative diagnostic solutions. Sales professionals can capitalize on this by promoting these unique testing services to healthcare providers, pharmacies, and medical facilities seeking cutting-edge diagnostic capabilities.

Specialized interpretation guides The development of specialized interpretation guides, such as the Interpretation Guide for Organic Acids Profile, showcases US BioTek's dedication to providing comprehensive resources for clinicians. Sales reps can utilize these guides as value-added tools in engaging with healthcare professionals who prioritize in-depth test result analysis and patient care.

Expert leadership in place With the appointment of Jack Frausing as President and CEO, US BioTek Laboratories has strengthened its leadership team with an industry expert. Sales development representatives can leverage this fact to instill confidence in potential clients about the company's strategic direction and vision for growth.

Strong financial backing Following the acquisition by Pike Street Capital and reporting revenue in the range of $10M - $50M, US BioTek Laboratories demonstrates financial stability and potential for further expansion. This financial health can be used as a selling point to establish trust with clients looking for reliable partners in the healthcare industry.